Lantheus Holdings, Inc. (LNTH)

Market Cap	6.21B
Revenue (ttm)	1.50B
Net Income (ttm)	427.61M
Shares Out	69.53M
EPS (ttm)	6.02
PE Ratio	14.83
Forward PE	13.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,984,612
Open	91.05
Previous Close	91.94
Day's Range	88.56 - 91.69
52-Week Range	50.20 - 126.89
Beta	0.46
Analysts	Strong Buy
Price Target	132.67 (+48.59%)
Earnings Date	Nov 6, 2024

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 834
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH
• Website: https://www.lantheus.com

Financial Performance

In 2023, Lantheus Holdings's revenue was $1.30 billion, an increase of 38.65% compared to the previous year's $935.06 million. Earnings were $326.66 million, an increase of 1063.86%.

Analyst Forecast

According to 6 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $132.67, which is an increase of 48.59% from the latest price.

Price Target

$132.67

(48.59% upside)

Analyst Consensus: Strong Buy